Development of liposomes containing indacaterol maleate and ciclesonide for pulmonary delivery
Friday, July 18, 2025
8:29 AM - 8:40 AM EDT
Location: 122 B
Introduction: This study aims to develop an innovative liposomal formulation loaded with ciclesonide (CIC) and indacaterol maleate (IND) for pulmonary administration. The goal is to enhance their mucopenetration, prevent degradation by macrophages, and improve uptake by epithelial cells. We first evaluated the impact of various PEGylated lipids (DSPE-PEG, DPPE-PEG, DMPE-PEG, DSG-PEG, DMG-PEG, and C8-Ceramide-PEG) on different properties of liposomes.
Learning Objectives:
At the completion of this activity, participants will know
Improve liposomes mucopenetration by using high concentrations of PEGylated lipids
Explain the impact of PEGylated lipids on the encapsulation of ciclesonide and indacaterol maleate
Explain the toxicity of different PEGylated lipids on macrophages
Benedetta Bottero – PhD student, Laboratory of Biology of Tumor and Development, University of Liege, Belgium; Laure-Anne Bya – PhD student, Laboratory of Pharmaceutical Technology and Biopharmacy, University of Liege, Belgium; Anna Lechanteur – Associate Professor, Laboratory of Pharmaceutical Technology and Biopharmacy, University of Liege, Belgium; Brigitte Evrard – Professor, Laboratory of Pharmaceutical Technology and Biopharmacy, University of Liege, Belgium; Didier Cataldo – Professor, Laboratory of Biology of Tumor and Development, University of Liege, Belgium; Géraldine Piel – Professor, Laboratory of Pharmaceutical Technology and Biopharmacy, University of Liege, Belgium
